Eight international EOS Centers will undertake a multi-center
study to evaluate the technology as a predictive tool

September 28, 2015 12:57 PM Eastern Daylight Time

PARIS--(BUSINESS WIRE)--EOS imaging (Paris:EOSI)(Euronext, FR0011191766 – EOSI), the pioneer in
2D/3D orthopedic medical imaging, today announced that it has acquired
the rights to an exclusive, worldwide license for a technology dedicated
to the prognosis of adolescent scoliosis using 3D and 2D clinical
parameters obtained from EOS® systems. A multi-center clinical study has
launched in 8 centers equipped with EOS systems (in the United States,
Canada, France, Japan, Singapore and Hong Kong) to measure the
technology’s ability to predict the risk of young patients with mild
scoliosis later developing a severe deformity.

Marie Meynadier, CE0 says: “This promising technology confirms the
value of the 3D data naturally associated with EOS images in developing
applications and services dedicated to orthopedic care pathways.
Acquiring these exclusive rights is an integral part of our global
strategy to offer doctors not only cutting-edge imaging technology, but
also a full suite of software and services to help them in their
therapeutic strategies and execution, to the greatest benefit to
patients.”

This software’s algorithm, developed by Montreal-based surgeons and
engineers, uses several clinical parameters available in patient reports
from the sterEOS workstation. It establishes a predictive score, which
could measure the risk of a patient at an early, mild stage of scoliosis
developing a severe form of the pathology. Preliminary data on this
predictive score will be presented at the forthcoming 50th
Scoliosis Research Society (SRS) Meeting to be held in Minneapolis,
Minnesota, from September 30th to October 3rd.

Treating scoliosis, whether via surgery or using a brace, is invasive.
The ability to predict the risk of scoliosis progressing can facilitate
both the choice of therapy – surgery or a brace – and its acceptance by
young patients. Although its efficacy has been proven, wearing a brace
can be difficult to accept for adolescent patients. In this area, EOS
imaging is also involved in programs targeting the improvement of brace
design using 3D information of the spine, ribcage and patient body
contours.

The EOS platform provides 2D and 3D full-body, stereo-radiographic
images of patients in functional positions. EOS exams require a
radiation dose 50% to 85% less than Digital Radiology and 95% less than
basic CT scans. The new EOS Micro Dose system, recently cleared by the
Food and Drug Administration, marks another important step towards the
ALARA principle (As Low As Reasonably Available). This latest technology
has made the dose for a pediatric spine follow-up exam equivalent to a
week of natural background radiation on Earth.

Next press release: revenue for the 3rd quarter of 2015, on October
21, 2015 (after market).

About EOS imaging

EOS imaging designs, develops, and markets EOS, an innovative medical
imaging system dedicated to osteoarticular pathologies and orthopaedics,
as well as associated solutions. The Company is authorized to market in
48 countries, including the United States (FDA), Japan and the European
Union (EC). The Group posted 2014 revenues of €20.1 million and employs
107 people including an R&D team of 39 engineers. The Group is based in
Paris and has five subsidiaries in Besançon (France), Cambridge
(Massachusetts), Montreal (Canada), Frankfurt (Germany) and Singapore.